This form is co	mpleted at in-clinic mid-	year visits (0°	IM, 02M, 03M)			
Form F01 reco medications.	rds the following: weight	, blood pressu	ure, serious adver	se events, study m	etformin status	and concomitant
Part I / IDENI	IFICATION					
	nt Identification					
1. Clini	c number					
2. Part	cipant number					
3. Nick	name					
4. Date	e of randomization				month day	 year
5. Sex				1	Male 1	Female 2
6. Out	come visit					VISIT
7. Date	e of visit				month day	QVST year replac DAYS

Form entered in computer?

Identification code of person reviewing completed form

ticipant ID		Nickname Outcome visit	DPPOS F01.6 July 2013 Page 2 of 4
<u>Pa</u>	art II / PH\	YSICAL AND HISTORY	
В.	Blood Pr	<u>Pressure</u>	
	1. Se	eated Arm Blood Pressure	
	a.		QPDBP1 mmHg
	b.	Blood Pressure Reading 2 (after waiting 30 seconds) QPSBP2 /	QPDBP2
	• The	n participant and PCP via letter if e participant is NON-DIABETIC and if systolic BP ≥ 140 or diastolic BP ≥ 90 on the mean of 1a and 1I OR e participant is DIABETIC and if systolic BP ≥ 130 or diastolic BP ≥ 80 on the mean of 1a and 1b.	5.
C.	Anthrop	<u>pometrics</u>	
	For C.1	1 - record Measure 3 only if first 2 measurements are not within 0.2 Kilograms (200g).	
	1. Wei	Measure 1 Measure 2 Measure 2 ight QPWGHT1 QPWGHT2 QPWGHT3	kg
D.	QueAt ttraiAt sEyeede	uery the participant for any events or procedures experienced since the last contact or visit. the visit during which a participant is queried for eye, gastric reduction, renal failure and kidney ansplant procedures for the first time, ask the participant if s/he underwent any of these procedure indomization in DPP. subsequent visits, query for procedures done since the last contact or visit. e procedures to be queried are: laser/Intravitreal treatment for diabetic retinopathy or diabetic mema, or other retinal procedures/surgeries. astric reduction surgeries include reversals of prior surgeries.	
	1. Sinc	ce the last contact or visit, has the participant experienced any of the following? CHECK ALL THAT APPLY	
	a.	Any acute life threatening event?	
	b.	Permanent or severe disability?	
	C.	Required or prolonged hospitalization?	
	d.	Overdose of any medication?	
	e.	Plednancy resulting in condential appointable of pitting defects and the second of the	f checked, complete 508 for each event.
	f.	Required intervention or treatment to prevent serious adverse event?	
	g.	Possible CVD event?	
	h.	Renal failure?	
	i.	Kidney transplant?	

			1
			July 20 Page 3
			• •
i Evo procedure?		1	ma valata
j. Eye procedure?			mplete
k. Gastric reduction surge	ry?		mplete
	cked, complete a separate E08 for eac ospitalization, complete an E08 for the		s that
	ame hospitalization) on the same E08 f		
If option j is checked, complet	te an E09 form. If option k is checked, o	complete an E11 form.	
III / MLS PARTICIPANT SECTION			
omplete sections E and F for all MLS	S participants.		
1etformin Status			
			QMTAI
 Has the participant taken ar since the last visit? 	ny Study Metformin	Yes 1 N	2 Jo
		163 14	10
		163	
	ormin Safety & Adherence Form for this		
	ormin Safety & Adherence Form for this		10
	ormin Safety & Adherence Form for this		
IF YES, complete the F08 Metfo	formin Safety & Adherence Form for this		
IF YES, complete the F08 Metfo	ormin Safety & Adherence Form for this		
IF YES, complete the F08 Metformin Complete the Metformin Safety Asse	formin Safety & Adherence Form for this	s participant.	
IF YES, complete the F08 Metformin	<u> </u>	s participant.	
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed.	essment Checklist for all participants re	ceiving study metformin before	
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed.	essment Checklist for all participants re	ceiving study metformin before	
IF YES, complete the F08 Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin	essment Checklist for all participants re	ceiving study metformin before QMDIS	iP.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed.	essment Checklist for all participants re	ceiving study metformin before QMDIS	iP.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin	essment Checklist for all participants re	ceiving study metformin before QMDIS	iP.
IF YES, complete the F08 Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin	essment Checklist for all participants re	ceiving study metformin before QMDIS	iP.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin	essment Checklist for all participants re	ceiving study metformin before QMDIS	iP.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin	rmin was dispensed (0, 3, 6)? Remove label from metformin	ceiving study metformin before QMDIS before dispensing and affix h	ere.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin METFORMIN LABEL	essment Checklist for all participants re	ceiving study metformin before QMDIS before dispensing and affix h	ere.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin METFORMIN LABEL	rmin was dispensed (0, 3, 6)? Remove label from metformin	ceiving study metformin before QMDIS before dispensing and affix h	ere.
Dispensing of Metformin Complete the Metformin Safety Assemetformin is dispensed. 1. How many months of metformin METFORMIN LABEL	rmin was dispensed (0, 3, 6)? Remove label from metformin	ceiving study metformin before QMDIS before dispensing and affix h	ere.

IF metformin is NOT dispensed for reasons other than a previously reported permanent condition, a Metformin Discontinuation Form (Form F07) must be completed.

Complete this section for all participants. G. Concomitant Medications 1. Has the participant taken any PRESCRIPTION medications within the past 2 weeks (excluding study metformin)? If YES. a. Total number of medications taken (including any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1. Medicine Description 2. Medicine Description 4. Medicine Description 7. Medicine Description 8. Medicine Description 1. Medicine Description 2. Medicine Description 3. Medicine Description 4. Medicine Description 1. Medicine Description 1. Medicine Description 2. Medicine Description 3. Medicine Description 4. Medicine Description 1. Medicine Description 2. Medicine Description 3. Medicine Description 4. Medicine Description 4. Medicine Descript	Participant ID Nickname	Outcome visit		DPPOS F01.6 July 2013 Page 4 of 4
S. Concomitant Medications 1. Has the participant taken any PRESCRIPTION medications within the past 2 weeks (excluding study metrormin)? If VES. a. Total number of medications taken (including any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1. Route 2	Part IV / CONCOMITANT MEDICATIONS			
1. Has the participant taken any PRESCRIPTION medications within the past 2 weeks (excluding study metrormin)? If YES. a. Total number of medications taken (including any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1.	Complete this section for all participants.			
medications within the past 2 weeks (excluding study metformin)? If YES. a. Total number of medications taken (including any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1.	G. Concomitant Medications			
a. Total number of medications taken (including any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1.	medications within the past 2 weeks (e		MRXDQ _{Yes} 1	
any medications listed on supplemental sheets) b. List medications below: QMDRUG1-30 Medicine Description 1.	If YES,			
Medicine Description	 Total number of medications taker any medications listed on supplem 	n (including ental sheets)		QMTOTMEDS
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.	b. List medications below: QMDR	UG1-30		
2.		cription		Route
3.	1.			
4.	2.			
5.	3.			
5.				
6.	4.			
7.	5.			
8.	6.			
8.	7.			
9.				
10.	8.			
11.	9.			
12	10.			
12	11			
13	11.			
14.	12.			
	13.			1
	14			
15.				
	15.			

Specify additional medications by appending the CONMED supplemental sheet to this form as needed.